logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Anemia Sickle Cell

    Medications for Anemia Sickle Cell

    FiltersReset Filters
    7 results

    • adakveo

      (crizanlizumab)
      Novartis Pharmaceuticals Corporation
      Usage: ADAKVEO® is indicated for reducing the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 and older with sickle cell disease.

    • desmopressin acetate

      (Desmopressin acetate)
      Meitheal Pharmaceuticals Inc.
      Usage: Desmopressin Acetate Injection is indicated for managing central diabetes insipidus, temporary polyuria and polydipsia post-head trauma or surgery, hemophilia A, and mild to moderate von Willebrand's disease (Type I). It helps maintain hemostasis and reduce bleeding during surgeries and after injuries. Not effective for nephrogenic diabetes insipidus.

    • droxia

      (HYDROXYUREA)
      H2-Pharma LLC
      Usage: DROXIA is indicated for reducing the frequency of painful crises and minimizing the need for blood transfusions in patients with sickle cell anemia who experience recurrent moderate to severe painful crises.

    • ferriprox

      (deferiprone)
      Chiesi USA, Inc.
      Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for myelodysplastic syndrome or Diamond Blackfan anemia.

    • ferriprox

      (deferiprone)
      Chiesi USA, Inc.
      Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for use in myelodysplastic syndrome or Diamond Blackfan anemia.

    • siklos

      (hydroxyurea)
      Medunik
      Usage: SIKLOS® is indicated for reducing the frequency of painful crises and the need for blood transfusions in adults and pediatric patients, 2 years and older, suffering from sickle cell anemia with recurrent moderate to severe painful crises.

    • xromi

      (Hydroxyurea)
      Nova Laboratories, Ltd.
      Usage: XROMI is indicated for pediatric patients aged 6 months and older with sickle cell anemia to reduce the frequency of painful crises and the need for blood transfusions.